Identification of Transcription factors involved in cisplatin drugresistance in ovarian cancer by integrated analysis of transcriptomeand epigenomic data

Ovarian cancer causes ۱۴۰,۲۰۰ deaths each year and is typically diagnosed at a late stage. Standard treatmentsfor newly diagnosed ovarian cancer are surgery and platinum-based chemotherapy like cisplatin. Ovarian can cer at diagnosis is typically very responsive to platinum-based chemotherapy. However, it frequently relapsesand becomes increasingly resistant to chemotherapy. Consequently, it is essential to understand the mechanismsunderlying platinum resistance and find ways to overcome them. here we used integrated analysis of RNA-seq ,CHIP-seq data to find transcription factors that are the core player of cisplatin resistance. First, we find di↵eren tially expressed genes by analysis of A۲۷۸۰ cisplatin sensitive and resistance cell lines RNA-seq data from threedatasets (PRJNA۷۲۴۶۸۰, PRJNA۳۸۴۳۵۲ & PRJNA۷۳۵۳۹۷). In order to find pathways involved in resistance tocisplatin we performed functional enrichment analysis, including GO (Gene Ontology) and KEGG (Kyoto Encyclo pedia of Genes and Genomes) pathway analysis. We then analyzed CHIP-seq data to find differentially acetylatedenhancers. By integrated analysis of transcriptome and epigenomic data we find transcription factors that tar get up regulated genes in resistant cell lines. Among these transcription factors, some of them are upregulatedin cisplatin-resistant cell lines, which can be further studied to design drugs that improve response to cisplatin.

کلیدواژه ها:

cisplatin resistance ، ovarian cancer ، transcription factors